The standard for acne by the Dutch College of General Practitioners;NHG-standaard acne: Tweede herziening

Huisarts en Wetenschap

Volumn 50, Issue 6, 2007, Pages 259-268

  Smeets, J G E ^a   Grooten, S J J ^a   Bruinsma, M ^a   Jaspar, A H J ^a   Kertzman, M G M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZOYL PEROXIDE; CLINDAMYCIN; CONTRACEPTIVE AGENT; DOXYCYCLINE; ERYTHROMYCIN; MINOCYCLINE; TETRACYCLINE;

ACNE CONGLOBATA; ACNE VULGARIS; CLINICAL PROTOCOL; GENERAL PRACTICE; HUMAN; REVIEW; STANDARD; TREATMENT INDICATION;

EID: 34447567370     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Bij verwijzingen naar NHG-producten: zie www.nhg.org.
2. Aronson J. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Amsterdam: Elsevier, 2006.
3. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004;CD004425.
4. Ballanger F, Baudry P, N'Guyen JM, Khammari A, Dreno B. Heredity: a prognostic factor for acne. Dermatology 2006;212:145-9.
5. Barth JH, Donald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993;129:704-7.
6. Bataille V, Snieder H, MacGregor AJ, Sasieni P, Spector TD. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol 2002;119:1317-22.
7. Bojar RA, Hittel N, Cunliffe WJ, Holland KT. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995;49 Suppl 2:164-7.
8. Bruinsma W. A guide to drug eruptions, side effects in dermatology. 7th ed. Amsterdam: IMP, 2000.
9. Burton JL, Cunliffe WJ, Stafford I, Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971;85:119-26.
10. Callender V. Acne in ethnic skin: special considerations for therapy. Dermatol Ther 2004;17:184-95.
11. Callender V. Considerations for treating acne in ethnic skin. Cutis 2005;76:19-23.
12. Chuh AA, Zawar V, Wong WC, Lee A. The association of smoking and acne in men in Hong Kong and in India: a retrospective case-control study in primary care settings. Clin Exp Dermatol 2004;29:597-9.
13. College ter Beoordeling van Geneesmiddelen. Samenvatting van de kenmerken van het product (2005). http://www.cbg-meb.nl/IB-teksten/10305-10306.pdf.
14. Commissie Farmaceutische Hulp van het College voor zorgverzekeringen. Farmacotherapeutisch Kompas: medisch farmaceutische voorlichting. Amstelveen: CVZ, 2006.
15. Cordain L. Implications for the role of diet in acne. Semin Cutan Med Surg 2005;24:84-91.
16. Cunliffe W, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002;12:350-4.
17. Cunliffe W, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139 Suppl 52:48-56.
18. Czernielewski J, Poncet M, Mizzi F. Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris. Cutis 2002;70:243-8.
19. De Gier JJ, Commentaren Medicatiebewaking. Houten: Stichting Health Base, 2006.
20. Dekkers M, Romijn JA, Smit JWA. Acne vulgaris: endocriene aspecten. Ned Tijdschr Geneeskd 2006;150:1281-5.
21. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000;21:363-92.
22. DiGiovanna JJ. Systemic retinoid therapy. Dermatol Clin 2001;19:161-7.
23. Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg 2001;20:209-14.
24. Draelos ZD, DiNardo JC. A re-evaluation of the comedogenicity concept. J Am Acad Dermatol 2006;54:507-12.
25. Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004;14:391-9.
26. Eady EA, Cove JH, loanes DN, Cunliffe WJ. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990;215-26.
27. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003a;4:813-31.
28. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem Dermatology 2003b;206:54-6.
29. Ebling F, Cunliffe W. Textbook of dermatology; Disorders of the sebaceous glands. 5th ed. Oxford: Blackwell Scientific Publications, 1994.
30. Farrar MD, Ingham E. Acne: inflammation. Clin Dermatol 2004;22:380-4.
31. Firooz A, Sarhangnejad R, Davoudi SM, Nassiri-Kashani M. Acne and smoking: is there a relationship? BMC Dermatol 2005;5:2.
32. Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003;CD002086.
33. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49:S1-37.
34. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999;141:297-300.
35. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004;292:726-35.
36. Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol 1998;39:S98-103.
37. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992;17:165-8.
38. Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005;23:665-74.
39. Hull PR, D'Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 2003;4:493-505.
40. Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol 2001;15 Suppl 3:37-42.
41. Jappe U. Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol 2003;83:241-8.
42. Jordan RE, Cummins CL, Burls AJ, Seukeran DC. Laser resurfacing for facial acne scars. Cochrane Database Syst Rev 2001;CD001866.
43. Klaz I, Kochba I, Shohat T, Zarka S, Brenner S. Severe acne vulgaris and tobacco smoking in young men. J Invest Dermatol 2006.
44. Kligman AM. An overview of acne. J Invest Dermatol 1974;62:268-87.
45. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Informatorium Medicamentorum. Den Haag: KNMP/WINAp, 2006.
46. Koreck A, Pivarcsi A, Dobozy A, Kemeny L. The role of innate immunity in the pathogenesis of acne. Dermatology 2003;206:96-105.
47. Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005;30:215-20.
48. Layton AM. A review on the treatment of acne vulgaris. Int J Clin Pract 2006;60:64-72.
49. Lehmann HP, Andrews JS, Robinson KA, Holloway VL, Goodman SN. Management of acne. Evid Rep Technol Assess (Summ) 2001;1-3.
50. Lestringant GG, Frossard PM, Agarwal M, Galadari IH. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol 1997;36:859-62.
51. Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis 2004;73:6-10.
52. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006;54:73-81.
53. Liao DC. Management of acne. J Fam Pract 2003;52:43-51.
54. Lidegaard O. Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol. J Obstet Gynaecol Can 2003;25:575-7.
55. Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005a;55:134-8.
56. Magin P, Pond D, Smith W, Watson A. A systematic review of the evidence for myths and misconceptions' in acne management: diet, face-washing and sunlight. Fam Pract 2005b;22:62-70.
57. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-6.
58. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005;24:92-102.
59. Mills CM, Peters TJ, Finlay AY. Does smoking influence acne? Clin Exp Dermatol 1993;18:100-1.
60. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986;25:664-7.
61. Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess 2005;9:iii-212.
62. Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AL, O'Neill C, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004;364:2188-95.
63. Pawin H, Beylot C, Chivot M, Faure M, Poli E Revuz J, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004;14:4-12.
64. Pearl A, Arroll B, Lello J, Birchall NM. The impact of acne: a study of adolescents' attitudes, perception and knowledge. N Z Med J 1998;111:269-71.
65. Purdy S, De Berker D. Acne. BMJ 2006a;333:949-53.
66. Purdy S, Acne Vulgaris. Clin Evid 2006b;15:2183-201.
67. Quereux G, Volteau C, N'Guyen JM, Dreno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006;212:168-76.
68. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003;148:467-78.
69. Rothman KF Pochi PE. Continuing medical education (Therapy): use of oral and topical agents for acne in pregnancy. Journal of the American Academy of Dermatology 2006;16:431-42.
70. Saurat JH. Systemic retinoids. What's new? Dermatol Clin 1998;16:331-40.
71. Schafer T, Nienhaus A, Vieluf D, Berger J, Ring J. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001;145:100-4.
72. Seaman HE, De Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003;18:522-6.
73. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005;153:395-403.
74. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005;27:1329-42.
75. Spitzer W. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation. J Obstet Gynaecol Can 2003;25:1011-8.
76. Tallab T, Joharji H, Jazei M, Bahamdan K, Ibrahim K, Karkashan E. Isotretinoin therapy: any need for laboratory assessment? West Afr J Med 2004;23:273-5.
77. Tan A, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother 2005;6:409-18.
78. Tan J. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett 2004;9:1-3, 9.
79. Tan J, Vasey K, Fung KY. Beliefs and perceptions of patients with acne. J Am Acad Dermatol 2001;44:439-45.
80. Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol 2002;46:S98-106.
81. Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 2001;15 Suppl 3:57-61.
82. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005;4:138-46.
83. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006;142:597-602.
84. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998;196:130-4.
85. Van 't Erve E, Bijl D. Adapaleen. Gebu 2006;11:125-6.
86. Van Broekhoven F, Verkes R, Janzing J. Psychiatrische verschijnselen bij gebruik van isotretoine. Ned Tijdschr Geneeskd 2003;147:2341-3.
87. Van de Lisdonk EH, Van den Bosch WJHM, Lagro-Janssen ALM. Ziekten in de huisarts-praktijk. Maarssen: Elsevier Gezondheidszorg, 2003.
88. Van der Geer S. Behandeling van keloïden en hypertrofische littekens. Ned Tijdschr Dermatol Venereol 2005;15:424-30.
89. Van der Linden M, Westert G, De Bakker D, Schellevis F. Tweede nationale studie naar ziekten en verrichtingen in de huisartspraktijk. Utrecht: Nivel, 2004.
90. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427-9.
91. Warner GT, Plosker GL. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Am J Clin Dermatol 2002;3:349-60.
92. Webster GF. The pathophysiology of acne. Cutis 2005;76:4-7.
93. Wessels F, Anderson AN, Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part 1. A meta-analysis of effectiveness literature. S Afr Med J 1999;89:780-4.
94. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998;134:376-8.
95. Wolf JE, Jr., Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003;49:S211-7.
96. Wolf R, Matz H, Orion E. Acne and diet. Clin Dermatol 2004;22:387-93.
97. Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol 1983;119:987-93.